ST Josephs Hospital of Buckhannon INC

ST Josephs Hospital of Buckhannon INC was paid $41.86M by Medicaid between Jan 2018 and Dec 2024, across 307 billing codes. Its largest line is 99283, emergency room visit (moderate) — 8.9% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	101,776	$6.25M
2019	78,442	$4.73M
2020	150,503	$10.73M
2021	150,895	$7.36M
2022	105,271	$4.52M
2023	127,051	$4.62M
2024incomplete	88,281	$3.65M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	8.9%	24,014	20,107	$3.73M
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	8.7%	21,614	16,834	$3.64M
85025	Blood count; complete (CBC), automated, and automated differential WBC count	4.2%	57,522	45,596	$1.75M
74177	Computed tomography, abdomen and pelvis; with contrast material	4.1%	2,263	2,016	$1.73M
70450	Computed tomography, head or brain; without contrast material	4.0%	2,950	2,684	$1.69M
80053	Comprehensive metabolic panel	3.7%	54,798	47,118	$1.54M
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	3.3%	9,026	7,730	$1.38M
99285	Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life	3.0%	7,865	5,924	$1.27M
74176	Computed tomography, abdomen and pelvis; without contrast material	2.6%	1,721	1,546	$1.08M
84443	Thyroid stimulating hormone (TSH)	2.3%	21,635	19,517	$962K
71045	Radiologic examination, chest; single view	1.6%	8,428	7,188	$678K
83036	Hemoglobin; glycosylated (A1C)	1.5%	20,506	18,587	$648K

295 more codes

87086	Culture, bacterial; quantitative colony count, urine	1.5%	14,441	$618K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	1.5%	11,785	$616K
80061	Lipid panel	1.4%	23,661	$604K
81001		1.4%	20,334	$579K
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	1.4%	9,920	$576K
36415	Collection of venous blood by venipuncture	1.4%	54,347	$568K
71046	Radiologic examination, chest; 2 views	1.3%	4,821	$560K
96375	Therapeutic injection; each additional sequential IV push	1.2%	7,945	$522K
88305	Level IV - Surgical pathology, gross and microscopic examination	1.2%	4,071	$483K
99282	Emergency department visit for the evaluation and management, low to moderate severity	1.1%	5,523	$464K
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	1.1%	1,770	$447K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	1.0%	22,670	$438K
G0378	Hospital observation service, per hour	<1%	3,362	$400K
80048	Basic metabolic panel (calcium, ionized)	<1%	15,530	$384K
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	<1%	1,538	$381K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	6,702	$356K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	3,742	$309K
76830	Ultrasound, transvaginal	<1%	871	$306K
73630		<1%	3,004	$297K
85027		<1%	9,808	$289K
82248		<1%	14,261	$266K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	5,133	$266K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	5,131	$259K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	5,532	$256K
96361	Intravenous infusion, hydration; each additional hour	<1%	5,662	$255K
86803		<1%	5,701	$251K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	3,679	$245K
59025	Fetal non-stress test	<1%	2,117	$231K
99213	Doctor's office visit, returning patient (routine)	<1%	21,912	$226K
84484		<1%	9,164	$224K
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	324	$223K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	4,013	$222K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	805	$217K
83690		<1%	9,647	$216K
72125	Computed tomography, cervical spine; without contrast material	<1%	315	$210K
67028	Intravitreal injection of a pharmacologic agent	<1%	1,997	$201K
92134		<1%	3,078	$201K
87186		<1%	4,328	$199K
J7120	Ringers lactate infusion, up to 1000 cc	<1%	3,821	$185K
85610		<1%	8,063	$185K
82607		<1%	3,306	$177K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	<1%	1,664	$176K
76816	Ultrasound, pregnant uterus, real time with image documentation, follow-up	<1%	723	$162K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	6,418	$161K
82803		<1%	3,693	$151K
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	1,504	$148K
73610		<1%	1,064	$144K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	5,677	$140K
83880		<1%	3,523	$139K
87077		<1%	4,304	$137K
71275	Computed tomographic angiography, chest, with contrast material	<1%	203	$136K
73564		<1%	1,176	$133K
87040		<1%	2,019	$132K
77067	Screening mammography, bilateral, including computer-aided detection	<1%	920	$129K
87340		<1%	2,291	$128K
82728		<1%	2,598	$128K
84466		<1%	2,693	$123K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	4,315	$120K
85730		<1%	3,470	$115K
G0463	Hospital outpatient clinic visit for assessment and management of a patient	<1%	17,294	$115K
72110		<1%	634	$114K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	5,561	$108K
76805	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation	<1%	395	$106K
81025		<1%	3,996	$105K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	779	$104K
73030		<1%	1,105	$103K
74018		<1%	979	$93K
45384		<1%	197	$92K
73130		<1%	762	$89K
87522	Neg quan hep c or qual rna	<1%	581	$88K
85652		<1%	2,889	$88K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	1,160	$86K
86706		<1%	1,373	$84K
84702		<1%	1,224	$84K
84439		<1%	2,187	$83K
87070		<1%	1,170	$82K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	1,427	$80K
82570		<1%	3,545	$80K
11042	Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm	<1%	2,531	$79K
80050	General health panel	<1%	843	$78K
96376		<1%	2,211	$78K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	2,090	$74K
73110		<1%	672	$74K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	2,453	$74K
87807		<1%	1,955	$73K
83605		<1%	2,867	$71K
88142		<1%	1,469	$71K
87481		<1%	376	$70K
83735		<1%	5,726	$70K
71250		<1%	185	$69K
82746		<1%	1,127	$65K
87081		<1%	1,410	$61K
99214	Doctor's office visit, returning patient (more involved)	<1%	8,737	$60K
82043		<1%	3,426	$58K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	969	$58K
86592		<1%	1,582	$57K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	2,780	$57K
74019		<1%	427	$56K
86850		<1%	1,628	$56K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	6,109	$55K
83540		<1%	2,877	$53K
82962		<1%	4,723	$51K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	537	$50K
82550		<1%	2,424	$48K
76642		<1%	335	$47K
86140		<1%	3,196	$45K
74022		<1%	409	$45K
93971		<1%	268	$43K
87506		<1%	132	$42K
84153		<1%	1,053	$42K
90715		<1%	930	$42K
85379		<1%	911	$41K
86704		<1%	1,164	$40K
84145		<1%	1,516	$40K
93017		<1%	97	$38K
87205		<1%	1,283	$37K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	223	$37K
86901		<1%	1,672	$36K
86618		<1%	989	$36K
84100		<1%	2,791	$35K
88342		<1%	492	$34K
86900		<1%	1,674	$34K
87653		<1%	395	$33K
96367		<1%	280	$30K
77063	Screening digital breast tomosynthesis, bilateral	<1%	677	$30K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	819	$30K
83970		<1%	258	$30K
86762		<1%	697	$29K
82274		<1%	766	$29K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	567	$27K
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	1,711	$25K
76536		<1%	135	$24K
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	<1%	63	$24K
76770		<1%	92	$24K
76817	Ultrasound, pregnant uterus, real time with image documentation, transvaginal	<1%	150	$24K
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	<1%	98	$23K
76813		<1%	263	$23K
11721		<1%	4,095	$22K
82947		<1%	720	$20K
73501		<1%	162	$19K
87799		<1%	74	$19K
99203	Doctor's office visit, new patient (routine)	<1%	1,811	$18K
J2270	Injection, morphine sulfate, up to 10 mg	<1%	1,005	$18K
J0178	Injection, aflibercept, 1 mg	<1%	55	$18K
99281	Emergency department visit for the evaluation and management, self-limited or minor	<1%	251	$17K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	1,476	$16K
45380	Colonoscopy, flexible; with biopsy, single or multiple	<1%	38	$16K
87493		<1%	203	$15K
82565		<1%	840	$15K
72072		<1%	83	$15K
86787		<1%	763	$15K
A9500	Technetium tc-99m sestamibi, diagnostic, per study dose	<1%	44	$15K
99204	Doctor's office visit, new patient (more involved)	<1%	2,356	$14K
86038		<1%	411	$14K
73080		<1%	124	$14K
85007		<1%	427	$13K
82105		<1%	366	$12K
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	406	$12K
80076		<1%	408	$12K
90686		<1%	880	$12K
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	1,087	$12K
84460		<1%	416	$11K
84703		<1%	341	$11K
93226		<1%	13	$11K
90472	Immunization administration, each additional vaccine (list separately)	<1%	625	$11K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	901	$11K
86780		<1%	663	$11K
10060		<1%	37	$10K
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	499	$10K
84156		<1%	264	$10K
84550		<1%	478	$9K
83001		<1%	205	$9K
82150		<1%	365	$9K
73140		<1%	76	$9K
76801		<1%	78	$8K
G0475	Hiv antigen/antibody, combination assay, screening	<1%	146	$8K
97597		<1%	549	$8K
82950		<1%	328	$8K
87147		<1%	248	$8K
81596		<1%	61	$7K
J2704	Injection, propofol, 10 mg	<1%	2,292	$7K
93010	Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only	<1%	3,765	$7K
86430		<1%	165	$7K
84520		<1%	291	$7K
84450		<1%	289	$7K
86200		<1%	109	$7K
82010		<1%	153	$6K
20610		<1%	155	$6K
83721		<1%	501	$6K
86695		<1%	219	$6K
87045		<1%	57	$6K
83002		<1%	88	$5K
87339		<1%	166	$5K
73090		<1%	30	$5K
86696		<1%	205	$5K
73562		<1%	32	$5K
76811	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed	<1%	15	$5K
99291	Critical care, evaluation and management of the critically ill patient, first 30-74 minutes	<1%	34	$4K
84146		<1%	25	$4K
84481		<1%	78	$4K
82140		<1%	187	$4K
81514		<1%	56	$4K
99173		<1%	241	$4K
87512		<1%	59	$4K
80164		<1%	67	$3K
80179		<1%	100	$3K
87075		<1%	31	$3K
73590		<1%	28	$3K
82553		<1%	70	$3K
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	<1%	12	$3K
83704		<1%	73	$3K
87427		<1%	66	$3K
83516		<1%	79	$3K
99219		<1%	99	$3K
93225		<1%	13	$3K
86431		<1%	63	$3K
73620		<1%	27	$3K
92551		<1%	174	$3K
86665		<1%	19	$3K
J1650	Injection, enoxaparin sodium, 10 mg	<1%	400	$3K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	31	$3K
J0131	Injection, acetaminophen, not otherwise specified,10 mg	<1%	338	$2K
87046		<1%	57	$2K
84403		<1%	82	$2K
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	<1%	22	$2K
99222	Initial hospital care, per day, moderate complexity	<1%	119	$2K
90670		<1%	204	$2K
73502		<1%	37	$2K
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	113	$2K
86617		<1%	109	$2K
76700	Ultrasound, abdominal, real time with image documentation; complete	<1%	13	$2K
J3490	Unclassified drugs	<1%	3,175	$2K
99393	Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years)	<1%	109	$2K
87177		<1%	39	$1K
Q9957	Injection, perflutren lipid microspheres, per ml	<1%	12	$1K
87328		<1%	24	$1K
99202	Office or other outpatient visit for the evaluation and management of a new patient, straightforward	<1%	120	$1K
84112		<1%	20	$1K
90658		<1%	100	$1K
87209		<1%	39	$1K
99392	Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years)	<1%	81	$1K
87329		<1%	24	$1K
99394	Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years)	<1%	78	$888.12
99391	Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year)	<1%	61	$874.24
82784		<1%	13	$862.89
J2360	Injection, orphenadrine citrate, up to 60 mg	<1%	108	$825.16
12001		<1%	16	$757.77
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	<1%	176	$723.40
86308		<1%	30	$722.30
C9257	Injection, bevacizumab, 0.25 mg	<1%	54	$719.38
84436		<1%	12	$711.19
J1642	Injection, heparin sodium, (heparin lock flush), per 10 units	<1%	64	$654.51
J0780	Injection, prochlorperazine, up to 10 mg	<1%	103	$641.30
92136		<1%	21	$588.95
90648		<1%	152	$578.47
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	29	$565.33
J0690	Injection, cefazolin sodium, 500 mg	<1%	58	$555.37
82247		<1%	12	$542.18
80143		<1%	49	$453.12
36600		<1%	14	$432.35
99217		<1%	42	$401.66
81002		<1%	12	$394.41
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	43	$368.49
86664		<1%	19	$353.65
99308	Subsequent nursing facility care, per day, straightforward	<1%	31	$317.08
94760		<1%	31	$310.25
T1015	A visit at a community health center or clinic (one all-in rate)	<1%	112	$300.22
90474		<1%	25	$270.12
82977		<1%	14	$245.99
83550		<1%	28	$227.95
J2060	Injection, lorazepam, 2 mg	<1%	64	$207.42
J2919	Injection, methylprednisolone sodium succinate, 5 mg	<1%	92	$206.12
90680		<1%	27	$183.50
90723		<1%	27	$179.50
83020		<1%	15	$150.04
90651		<1%	16	$143.33
83695		<1%	29	$142.23
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	250	$127.84
90620		<1%	12	$116.39
G0008	Administration of influenza virus vaccine	<1%	74	$103.68
90710		<1%	15	$71.61
11056		<1%	23	$67.76
99395	Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years	<1%	15	$60.54
82172		<1%	42	$57.45
J0134	Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg	<1%	43	$56.62
J0136	Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg	<1%	61	$52.81
G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	<1%	99	$40.33
90633		<1%	12	$34.36
99305		<1%	38	$30.00
J3475	Injection, magnesium sulfate, per 500 mg	<1%	17	$7.41
99442		<1%	28	$4.93
90734		0%	29	$0.00
99024		0%	34	$0.00
99441		0%	22	$0.00
Q0240	Injection, casirivimab and imdevimab, 600 mg	0%	20	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialJOHNSON-PHILLIPPE, SUE (CEO)